免疫编辑
免疫系统
免疫原性
癌症研究
免疫学
免疫抑制
生物
免疫疗法
作者
Xinchao Li,Xiuqi Liang,Wenxing Fu,Rui Luo,Miaomiao Zhang,Xiaorong Kou,Y Zhang,Yingjie Li,Dongxue Huang,Yanjie You,Qinjie Wu,Changyang Gong
标识
DOI:10.1016/j.bioactmat.2024.01.026
摘要
In situ vaccine (ISV) is a promising immunotherapeutic tactic due to its complete tumoral antigenic repertoire. However, its efficiency is limited by extrinsic inevitable immunosuppression and intrinsic immunogenicity scarcity. To break this plight, a tumor-activated and optically reinforced immunoscaffold (TURN) is exploited to trigger cancer immunoediting phases regression, thus levering potent systemic antitumor immune responses. Upon response to tumoral reactive oxygen species, TURN will first release RGX-104 to attenuate excessive immunosuppressive cells and cytokines, and thus immunosuppression falls and immunogenicity rises. Subsequently, intermittent laser irradiation-activated photothermal agents (PL) trigger abundant tumor antigens exposure, which causes immunogenicity springs and preliminary infiltration of T cells. Finally, CD137 agonists from TURN further promotes the proliferation, function, and survival of T cells for durable antitumor effects. Therefore, cancer immunoediting phases reverse and systemic antitumor immune responses occur. TURN achieves over 90 % tumor growth inhibition in both primary and secondary tumor lesions, induces potent systemic immune responses, and triggers superior long-term immune memory in vivo. Taken together, TURN provides a prospective sight for ISV from the perspective of immunoediting phases.
科研通智能强力驱动
Strongly Powered by AbleSci AI